Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)
NCT02296476 · Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · PHASE2 · terminated · last registry update 2021-01-26 · Glioblastoma · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This study was terminated due to lack of clinical activity and not due to safety reasons.” | Open Targets' class: negative | Registry record, Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against BRD2 in glioblastoma within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
No results, stops or Phase 3 starts on the same target in that window.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision